Quantum BioPharma Ltd. (NASDAQ: QNTM), a biopharmaceutical company developing therapies for neurodegenerative and metabolic disorders, has taken a significant step toward advancing its lead multiple sclerosis (MS) drug candidate. The company has signed a Study Start-Up Agreement with the clinical research business of Thermo Fisher Scientific, a leading global contract research organization (CRO), to implement the Phase 2 trial of Lucid-MS. This agreement transitions the program from planning into execution, following the U.S. Food and Drug Administration's clearance of its Investigational New Drug application in August.
The collaboration is important because Lucid-MS represents a novel approach to treating MS. Most existing MS drugs work by modulating the immune system, but Lucid-MS is designed to target demyelination—the damage to the protective myelin sheath around nerve fibers—rather than solely suppressing immune activity. "Following FDA clearance to proceed with the phase 2 study, initiating study start-up activities with a leading global CRO with extensive CNS and MS experience represents an important next step," said Quantum BioPharma CEO Zeeshan Saeed. The trial will evaluate the efficacy, safety, and tolerability of Lucid-MS in people with progressive MS, a form of the disease with limited treatment options.
MS affects an estimated 3 million people worldwide, including nearly 1 million in the United States. Progressive forms of MS, which are the focus of the Lucid-MS trial, often lead to worsening disability over time. A 2023 study in Neurology and Therapy described treatment options for progressive MS as limited, with many patients remaining untreated or continuing to decline despite available therapies. A National MS Society report released this year identified urgent unmet needs, including effective treatment of disease progression and therapies that repair myelin damage. This underscores the potential impact of a neuroprotective approach like Lucid-MS.
Thermo Fisher's clinical research business, which Quantum acquired in 2021 for $17.4 billion, brings deep expertise in central nervous system and MS studies. "We're proud to partner with Quantum BioPharma in advancing their neuro-degenerative clinical program in multiple sclerosis," said Michael Cioffi, vice president and general manager, neuroscience, clinical research, at Thermo Fisher. "Our team brings deep experience in CNS and MS trials, along with an integrated approach that connects strategy and execution to help deliver these complex studies." The partnership provides Quantum with an experienced partner to navigate the complexities of a Phase 2 trial in progressive MS.
The commercial stakes are also notable. Quantum's announcement cites Grand View Research in projecting that the MS therapeutics market will exceed $38 billion by 2030. Lucid-MS is an investigational, first-in-class new chemical entity that targets peptidyl arginine deiminase 2 (PAD2), an enzyme implicated in the hypercitrullination of myelin proteins. By inhibiting PAD2, Lucid-MS aims to protect the integrity of the myelin sheath. In preclinical models, the compound has demonstrated the ability to prevent and reverse measures of myelin degradation, and it has shown a favorable safety profile in Phase 1 trials.
For more information, visit www.QuantumBioPharma.com. The latest news and updates relating to QNTM are available in the company's newsroom at https://ibn.fm/QNTM. This announcement was originally distributed by BioMedWire, a specialized communications platform focused on the biotechnology, biomedical sciences, and life sciences sectors. BioMedWire is part of the Dynamic Brand Portfolio at IBN, which provides access to a vast network of wire solutions via InvestorWire and other services. For full terms of use and disclaimers, please see https://www.BioMedWire.com/Disclaimer.
